Scarica l'app Stockscreener
2.72
1.81%
-0.05
Dopo l'orario di chiusura:
3.00
0.28
+10.29%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ACRS Giù?
Forum
Previsione
Precedente Chiudi:
$2.77
Aprire:
$2.74
Volume 24 ore:
1.15M
Relative Volume:
0.51
Capitalizzazione di mercato:
$194.29M
Reddito:
$31.25M
Utile/perdita netta:
$-88.48M
Rapporto P/E:
-1.7548
EPS:
-1.55
Flusso di cassa netto:
$-79.63M
1 W Prestazione:
-15.53%
1M Prestazione:
-31.31%
6M Prestazione:
+140.71%
1 anno Prestazione:
+190.91%
Intervallo 1D:
$2.71
$2.90
Intervallo di 1 settimana:
$2.71
$3.29
Portata 52W:
$0.8555
$5.17
Aclaris Therapeutics Inc Stock (ACRS) Company Profile
Nome
Aclaris Therapeutics Inc
Settore
Industria
Telefono
484-324-7933
Indirizzo
701 LEE ROAD, WAYNE, PA
Confronta ACRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACRS
Aclaris Therapeutics Inc
|
2.72 | 194.29M | 31.25M | -88.48M | -79.63M | -1.27 |
|
TMO
Thermo Fisher Scientific Inc
|
524.05 | 200.45B | 42.37B | 6.14B | 7.78B | 15.95 |
|
DHR
Danaher Corp
|
228.55 | 165.08B | 23.74B | 3.89B | 4.98B | 5.24 |
|
A
Agilent Technologies Inc
|
134.51 | 38.36B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IQV
Iqvia Holdings Inc
|
197.27 | 35.80B | 15.32B | 1.41B | 1.96B | 7.62 |
|
IDXX
Idexx Laboratories Inc
|
412.26 | 33.76B | 3.84B | 866.24M | 792.60M | 10.37 |
Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-20 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2024-11-19 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2024-11-19 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-19 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-18 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-01-22 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2023-11-13 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-03 | Iniziato | Evercore ISI | Outperform |
| 2022-12-14 | Iniziato | Stifel | Buy |
| 2022-12-01 | Iniziato | Goldman | Buy |
| 2022-10-06 | Iniziato | BTIG Research | Buy |
| 2021-07-23 | Ripresa | Jefferies | Buy |
| 2021-06-15 | Iniziato | Piper Sandler | Overweight |
| 2021-04-21 | Iniziato | H.C. Wainwright | Buy |
| 2019-10-22 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-06 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-06-27 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-05-06 | Iniziato | SVB Leerink | Outperform |
| 2018-03-28 | Ripresa | Leerink Partners | Outperform |
| 2018-02-09 | Iniziato | Guggenheim | Buy |
| 2017-06-16 | Iniziato | Cantor Fitzgerald | Overweight |
| 2016-11-29 | Iniziato | Leerink Partners | Outperform |
| 2016-09-30 | Iniziato | JMP Securities | Mkt Outperform |
| 2016-06-10 | Iniziato | Guggenheim | Buy |
| 2015-11-02 | Iniziato | Citigroup | Buy |
| 2015-11-02 | Iniziato | Jefferies | Buy |
Mostra tutto
Aclaris Therapeutics Inc Borsa (ACRS) Ultime notizie
Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $8.80 - MarketBeat
Fmr LLC Cuts Holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Financial Review: Aclaris Therapeutics (NASDAQ:ACRS) versus Theratechnologies (NASDAQ:THTX) - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Growth in Short Interest - Defense World
Aclaris Therapeutics Announces New Employee Stock Grants Under 2024 Inducement Plan - MSN
Aclaris Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference - MSN
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 59.0% in November - MarketBeat
Jacobs Levy Equity Management Inc. Takes Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
Aclaris Therapeutics, Inc. announced that it expects to receive $79.999999 million in funding from a group of investors - Marketscreener.com
Aclaris Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - GlobeNewswire
Wayne’s Aclaris Therapeutics Signs Exclusive Licensing Deal with Chinese Biotech - MSN
Connor Clark & Lunn Investment Management Ltd. Boosts Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World
Connor Clark & Lunn Investment Management Ltd. Grows Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Decrease in Short Interest - Defense World
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $8.80 Consensus Price Target from Brokerages - Defense World
Aclaris Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Equities Analysts Set Expectations for ACRS FY2024 Earnings - MarketBeat
Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $8.80 Average Price Target from Brokerages - MarketBeat
Aclaris Therapeutics Secures Exclusive Licensing for Novel Antibody Therapies - MSN
Aclaris Therapeutics secures global rights to Biosion’s antibodies - MSN
Rock Springs Capital Management LP Increases Stake in Aclaris Therapeutics Inc - GuruFocus.com
Aclaris Therapeutics And 2 Other US Penny Stocks To Watch - Simply Wall St
Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Cantor Fitzgerald - Defense World
Aclaris upgraded to overweight by Cantor on in-licensing deal - MSN
Aclaris Therapeutics enters into exclusive license agreement for two drugs - Pennsylvania Business Report
What is Leerink Partnrs' Estimate for ACRS FY2024 Earnings? - MarketBeat
Aclaris Therapeutics director acquires $1.5 million in stock By Investing.com - Investing.com Australia
Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by Leerink Partners - Defense World
Insider Buying: Anand Mehra Acquires Shares in Aclaris Therapeutics Inc (ACRS) - GuruFocus.com
Aclaris Therapeutics director acquires $1.5 million in stock - Investing.com India
Aclaris Therapeutics (NASDAQ:ACRS) Upgraded by Leerink Partnrs to Strong-Buy Rating - MarketBeat
Aclaris Therapeutics upgraded to Buy from Hold at Jefferies - MSN
Aclaris Therapeutics (ACRS) Reports Q3 Loss, Misses Revenue Estimates - MSN
S&P 500 Value (IVX) QuotePress Release - The Globe and Mail
Aclaris signs license deal for biologics assets - MSN
Aclaris Therapeutics Inc Azioni (ACRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Aclaris Therapeutics Inc Azioni (ACRS) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Mehra Anand | Director |
Nov 19 '24 |
Buy |
2.25 |
666,666 |
1,499,998 |
710,030 |
| Walker Neal | INTERIM PRESIDENT AND CEO |
Aug 09 '24 |
Option Exercise |
0.72 |
43,548 |
31,355 |
1,356,153 |
| Leonard Braden Michael | 10% Owner |
Aug 05 '24 |
Buy |
1.24 |
206,025 |
256,357 |
14,250,000 |
| Leonard Braden Michael | 10% Owner |
Aug 02 '24 |
Buy |
1.29 |
167,544 |
216,400 |
14,043,975 |
| Leonard Braden Michael | 10% Owner |
Jul 30 '24 |
Buy |
1.30 |
173,730 |
226,370 |
13,776,421 |
| Leonard Braden Michael | 10% Owner |
Jul 31 '24 |
Buy |
1.33 |
100,000 |
132,640 |
13,876,421 |
| Leonard Braden Michael | 10% Owner |
Jul 18 '24 |
Buy |
1.30 |
130,317 |
169,555 |
13,578,286 |
| Leonard Braden Michael | 10% Owner |
Jul 22 '24 |
Buy |
1.33 |
17,716 |
23,557 |
13,602,691 |
| Leonard Braden Michael | 10% Owner |
Jul 19 '24 |
Buy |
1.30 |
6,689 |
8,696 |
13,584,975 |
| Leonard Braden Michael | 10% Owner |
Jul 03 '24 |
Buy |
1.16 |
143,288 |
166,071 |
13,324,952 |
0.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):